Group 1 - The CEO of the company, Charles Divita, has a long history with Teladoc, having previously been an executive at a large health plan [1] - In 2018, the importance of Teladoc was recognized in discussions with brokers, highlighting its relevance to customer bases [1] - The company decided to roll out Teladoc services to all commercial members by the fall of 2019, prior to the pandemic [2] Group 2 - The pandemic significantly impacted the company's member engagement with Teladoc services [2]

4Q-25 Quarterly Results 4Q-25 Revenue of $642M, 0% y/y 4Q-25 Net loss per share of $(0.14)(1) 4Q-25 Adj. EBITDA(2) of $83.8M, 12% y/y FY-26 Revenue outlook range of $2,470M to $2,587M Cautionary Note 2 • This presentation contains, and the officers of Teladoc Health, Inc. (the "Company" or "Teladoc Health") may make, "forward-looking" statements that are based on management's beliefs and assumptions and on information currently available to management. These forward-looking statements include, without limit ...

Core Viewpoint - Hims & Hers Health Inc's stock plummeted 12.6% after the FDA issued a warning regarding the sale of unapproved compounded GLP-1 drugs, indicating a significant regulatory challenge for the company [1]. Regulatory Actions - The FDA is taking decisive actions against companies like Hims & Hers that sell compounded drugs as alternatives to approved treatments, aiming to protect consumers from unverified products [3]. - The FDA's intervention follows Hims & Hers' aggressive expansion, including the launch of a compounded semaglutide tablet priced at $49 per month, which the company claims is designed to enhance absorption [3]. - The FDA has warned that companies cannot claim unapproved compounded products are equivalent to FDA-approved drugs, indicating a tightening of regulations [3]. Competitive Landscape - Novo Nordisk, the manufacturer of the popular drug Wegovy, has responded by labeling Hims & Hers' new product as "unapproved, misleading, and untested," and plans to take legal and regulatory action against the company for "illegal mass compounding" [3]. - Novo Nordisk emphasizes that it remains the only manufacturer producing a legally approved oral semaglutide tablet using proprietary absorption technology [3]. Company Positioning - Hims & Hers executives argue that their platform provides essential accessibility and personalized services for patients who prefer non-injection methods [4]. - The company claims to have invested years in building the necessary infrastructure to offer personalized options to patients [4]. - The FDA's recent stance indicates an escalation in actions against misleading direct-to-consumer advertising, following previous warnings about unverified claims regarding compounded drugs [4]. Market Implications - The regulatory crackdown creates a volatile environment for telehealth investors, as Hims & Hers faces significant survival threats since its inception [5]. - The market is closely monitoring whether the FDA will follow through on its threats of legal action without prior notice, which could impact Hims & Hers' promised affordability [5].

Core Viewpoint - Company expects a net profit loss of 25 million to 36 million yuan for the full year of 2025 due to various challenges in the market and operational adjustments [1] Group 1: Performance Forecast - Company anticipates a net profit loss of 25 million to 36 million yuan for 2025 [1] - The forecasted loss is attributed to changes in the macro environment and the impact of centralized procurement policies in the in-vitro diagnostics industry [2] Group 2: Reasons for Performance Changes - The competitive landscape is being reshaped, leading to a decrease in product procurement prices and fluctuations in order volumes, which pose challenges to sales revenue and gross margin [2] - Despite cost-saving measures, fixed expenditures remain constant, and investments in talent optimization and capability upgrades have contributed to the expected losses [2] - The company is adjusting its business layout and strategy, focusing on the "ACME" proprietary products, increasing R&D investment, and expanding the market development team to enhance high-value services for hospital clients [2] Group 3: Financial Performance - For the first three quarters of 2025, the company's main revenue was 549 million yuan, a year-on-year decrease of 22.8% [3] - The net profit attributable to shareholders was -12.39 million yuan, a decline of 146.65% year-on-year [3] - The gross margin was reported at 15.84%, with a debt ratio of 27.18% [3]

Core Viewpoint - BFB HEALTH, formerly known as 财讯传媒集团, has officially rebranded as "BFB HEALTH," marking its position as the first publicly listed company in China's remote medical health management sector, with a market capitalization exceeding 1.2 billion HKD [1][3] Group 1: Company Overview - The rebranding ceremony took place in Bozhou, Anhui, which is recognized as the "World Capital of Traditional Chinese Medicine" [1] - BFB HEALTH's stock closed at 0.99 HKD, indicating strong market interest and confidence in the company's future [1] - The company plans to allocate 50% of its secondary market financing towards AI upgrades and new drug development, while the other 50% will focus on product iteration, brand building, and upgrading intelligent production lines [1][5] Group 2: Market Context - The National Healthcare Security Administration issued guidelines for remote surgical assistance pricing, paving the way for the commercialization of remote medical services [3] - The remote medical market in China has surpassed 100 billion CNY, with a compound annual growth rate of over 25% [8] - BFB HEALTH fills a gap in the market as the first dedicated player in the remote medical sector on the Hong Kong stock exchange, leveraging its regional advantages in traditional Chinese medicine [3][4] Group 3: Business Model and Strategy - BFB HEALTH's business model mirrors that of U.S. telehealth giant Hims & Hers, focusing on a closed-loop system of online diagnosis, product services, and health management [4] - The company employs a "1+N" strategy, utilizing a cross-border drug purchasing platform to support multiple independent brands, thereby addressing diverse health needs and creating competitive advantages [5] - BFB HEALTH aims to enhance user engagement through a subscription model, similar to Hims, which locks in long-term users and stabilizes cash flow [4] Group 4: Industry Impact - BFB HEALTH is set to drive digital transformation in the healthcare industry by utilizing digital channels and AI technology, thus improving service efficiency and accessibility [6] - The company promotes personalized health services, shifting the industry focus from product-driven to user-centered approaches [6] - As the first private enterprise listed in Bozhou, BFB HEALTH is expected to stimulate local economic growth and attract related businesses, enhancing the regional healthcare ecosystem [7]

Group 1 - BFB Health Limited, formerly known as 财讯传媒集团有限公司, officially changed its name on January 22, 2023, and aims to become the "first stock of remote medical health management in China" [1] - The company is based in Bozhou and is the first private enterprise listed in the region, leveraging local resources to grow into a national remote medical service platform [3] - The Chinese remote medical market is projected to exceed 100 billion yuan by 2025, with a compound annual growth rate of over 25%, positioning BFB Health as a leading player in the industry [3] Group 2 - BFB Health plans to allocate 50% of its secondary market financing to AI upgrades in the health industry and new drug development, while the other 50% will focus on product iteration, brand building, and upgrading intelligent production lines [3] - The company is driving digital transformation in the industry through online consultations and AI technology, enhancing service efficiency and coverage [4] - BFB Health is leading the trend of personalized health services by utilizing big data and AI to analyze user health needs, shifting the industry from a product-oriented to a user-oriented approach [4] Group 3 - The company is fostering regional industrial collaboration by enhancing the local supply chain, including traditional Chinese medicine cultivation and logistics, thereby attracting related enterprises to Bozhou [5] - BFB Health's development is expected to create numerous job opportunities, increase local tax revenue, and contribute to regional GDP growth [5] - The company aims to optimize service experiences through technological advancements, making online consultations more convenient and allowing users in remote areas to access quality medical services [5] Group 4 - Under the "Healthy China" strategy, remote medical services are seen as a core direction for digital transformation in healthcare, with significant future growth potential [5] - BFB Health, as an industry pioneer, is expected to continue deepening technological and model innovations, driving high-quality development in the sector [5]

Core Viewpoint - The National Healthcare Security Administration of China is promoting the large-scale application of surgical robotic arms by establishing a new pricing project for "remote surgical assistance" to enhance the integration of advanced medical technologies into healthcare services [1][2]. Group 1: Pricing Guidelines and Projects - The National Healthcare Security Administration has accelerated the compilation and issuance of medical service pricing project guidelines, having released a total of 36 batches, with provinces averaging 30 batches implemented [1]. - The 37th batch of guidelines includes 37 pricing projects specifically for surgical and treatment assistance operations, along with 5 additional charge items and 1 expansion item, covering key technologies such as 3D printing, intraoperative guidance, and surgical robotic arms [1][2]. Group 2: Focus on Surgical Robots - The pricing guidelines focus on the participation level of surgical robots in operations and their clinical value in precision surgery, categorizing pricing into navigation, execution participation, and precision execution [2]. - A coefficient-based charging model is implemented, allowing surgical robots with higher participation, comprehensive functions, and precise execution to receive higher fee coefficients [2]. Group 3: Remote Surgery and Resource Allocation - The establishment of the "remote surgical assistance fee" pricing project aims to facilitate remote surgeries conducted by experts in resource-rich areas for patients in other regions, thereby reducing the burden of travel for patients seeking quality medical care [2]. - The National Healthcare Security Administration is closely monitoring innovations in the medical industry and has unified over a hundred prospective pricing projects related to new technologies and products, paving the way for gradual industrial upgrades and leading healthcare payment innovations [2].

Core Insights - The company is focusing on smart healthcare, which is a key area supported by national policy [1] - The company collaborates with top research universities and medical institutions to develop clinical diagnostic assistance systems using AI and big data [1] - The company is actively seeking hospital partnerships for practical application of its systems and plans to continuously optimize based on feedback [1] Industry Developments - The national health commission is promoting the development of intelligent healthcare, providing a broad growth space for the industry [1] - The aging population and uneven distribution of medical resources highlight the need for AI-assisted diagnosis and remote medical services [1] - The company is committed to enhancing grassroots medical service capabilities through technology and service integration [1]

Core Insights - Jiangsu Cancer Hospital and Huai'an Cancer Hospital successfully performed two remote surgeries using 5G robotic technology, allowing local patients to access high-quality medical resources without leaving their city [1][2] Group 1: Remote Surgery Implementation - The first surgery involved the removal of two kidney lesions, completed in about one hour with no operational delays, providing a seamless experience similar to traditional robotic surgeries [2] - The second surgery focused on the removal of multiple lung nodules, with the largest nodule measuring approximately 1.5 centimeters, and was completed in about 30 minutes [2] Group 2: Training and Collaboration - Jiangsu Cancer Hospital has been providing ongoing support to Huai'an Cancer Hospital through management and expert teams, enhancing local medical capabilities over the past three years [3] - A systematic support plan was established to ensure the safety of remote surgeries, including advanced equipment and hands-on training for local medical staff [3] Group 3: Future Developments - Jiangsu Cancer Hospital has been approved as a national training base for AI-assisted treatment technologies, aiming to integrate AI deeply into cancer diagnosis and treatment [3][4] - Future developments in robotic surgery will focus on remote medical services and automated surgeries, with plans to implement "one-to-many" and "many-to-one" models for enhanced resource utilization [4]

Group 1: Economic Overview - In 2024, China's GDP exceeded 134.9 trillion yuan, growing by 5.0% year-on-year, ranking among the top major economies globally [2] - The economic structure continues to optimize, with the primary, secondary, and tertiary industries accounting for 6.8%, 36.5%, and 56.7% of GDP, respectively [2] - Consumption, investment, and net exports contributed 2.2, 1.3, and 1.5 percentage points to GDP growth, respectively [2] Group 2: Technological Advancements - China has made significant breakthroughs in cutting-edge technologies such as 6G communication, AI large models, and quantum computing [3] - The first international 6G field test network was established in July 2024, demonstrating potential 6G transmission capabilities [3] - China ranks second globally in the number of open-source participants, with rapid growth in the sector [3] Group 3: New Energy and Carbon Neutrality - The new energy sector has become a growth engine, with China accounting for over 60% of global new wind and solar installations in 2024 [4] - The installed capacity of new energy storage exceeded 70 million kilowatts, with leading companies like CATL and BYD holding a 65.5% market share in the global power battery market [4] - Solid-state battery technology has achieved mass production breakthroughs, with energy density exceeding 400 Wh/kg [4] Group 4: Healthcare Sector - The healthcare market is expanding due to aging population and rising health consumption demands, with government spending in the sector reaching 2.03 trillion yuan in 2024 [5] - AI-assisted diagnosis, gene editing, and telemedicine technologies are accelerating breakthroughs and applications in the industry [5] - Leading companies like WuXi AppTec and Mindray are actively pursuing globalization strategies to capture high-end medical equipment and biopharmaceutical markets [5] Group 5: Financial and Consumer Trends - The total assets of China's financial institutions reached 495.59 trillion yuan in 2024, growing by 7.5% year-on-year [6] - The banking sector's total assets were 444.57 trillion yuan, with a growth rate of 6.5% [6] - The rise of new retail and domestic brands is reshaping the consumer market, with companies like Luckin Coffee and Pop Mart leveraging data-driven strategies [6] Group 6: Emerging and Future Industries - Emerging industries such as new energy, aerospace, and quantum technology are driving economic growth and international competitiveness [7] - The low-altitude economy is projected to reach a market size of 1.5 trillion yuan by 2025 and 3.5 trillion yuan by 2035 [7] - The embodied intelligence market is expected to exceed 480 billion yuan in 2024, with potential to surpass one trillion yuan by 2031 [7] Group 7: Super CEO Recognition - The "Super CEO" list highlights leaders across various sectors, including healthcare, new energy, entertainment, and technology, showcasing their exceptional leadership and performance [8] - These CEOs have demonstrated resilience and strategic vision in navigating industry challenges and driving company growth [8]